Treasury Proposes Sweeping Curbs on U.S. Investment in Chinese Biotech and AI

Key points

• The Treasury proposal prohibits U.S. investment in Chinese biomanufacturing equipment, bio-derived compounds, and automated scientific discovery tools.
• The rules also cover artificial intelligence, supercomputing, and hypersonic systems, with a minimum investment threshold of $50,000.
• PhRMA and the Biotechnology Innovation Organization oppose the measures, arguing they hinder access to cutting-edge treatments and weaken U.S. competitiveness.
• Existing cash-based licensing deals by major drugmakers like Eli Lilly and Pfizer are exempt from the new restrictions.
• The proposal follows the 2025 law codifying the Outbound Investment Security Program and comes after a recent U.S.-China trade truce extension.

Background

This development follows a year of escalating U.S.-China tech tensions, including a temporary trade truce extended in September 2026. It also builds on earlier concerns about American patients seeking Chinese-developed cancer therapies due to FDA delays, highlighting the complex balance between national security and medical access.

How outlets are covering it

Politico emphasizes the conflict between the Treasury’s security goals and the pharmaceutical industry’s reliance on Chinese innovation, citing PhRMA’s opposition. The Financial Times highlights the breadth of the restrictions, noting they cover AI and hypersonic weapons alongside biotech, and points out the exemption for cash-based licensing deals. AP News focuses on the legal framework, linking the proposal to the 2025 Comprehensive Outbound Investment National Security Act and noting the inclusion of Russia and other adversaries, despite recent diplomatic shifts.

Why it matters

The proposed rules could significantly alter the flow of capital into China’s high-tech sectors, potentially slowing the development of dual-use technologies that pose national security risks. However, they may also limit U.S. access to innovative therapies and increase compliance costs for American companies, affecting global pharmaceutical and tech supply chains.

What to watch

The Treasury will accept public comments before finalizing the rules. Industry groups are expected to lobby for narrower definitions to protect legitimate business activities, while enforcement mechanisms may tighten in subsequent phases.